<SEC-DOCUMENT>0001193125-23-268939.txt : 20231102
<SEC-HEADER>0001193125-23-268939.hdr.sgml : 20231102
<ACCEPTANCE-DATETIME>20231102091059
ACCESSION NUMBER:		0001193125-23-268939
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231102
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231102
DATE AS OF CHANGE:		20231102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39979
		FILM NUMBER:		231370341

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d554165d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vor="http://vorbiopharma.com/20231102" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-11-02_to_2023-11-02">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-11-02_to_2023-11-02">0001817229</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="vor-20231102.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-11-02_to_2023-11-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001817229</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-02</xbrli:startDate> <xbrli:endDate>2023-11-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-11-02_to_2023-11-02">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt:datemonthdayyearen">November&#160;2, 2023</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-11-02_to_2023-11-02">Vor Biopharma Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-11-02_to_2023-11-02">001-39979</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-11-02_to_2023-11-02">81-1591163</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-11-02_to_2023-11-02">100 Cambridgepark Drive</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-11-02_to_2023-11-02">Suite 101</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-11-02_to_2023-11-02">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-11-02_to_2023-11-02">02140</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-11-02_to_2023-11-02">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-11-02_to_2023-11-02">655-6580</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-11-02_to_2023-11-02">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-11-02_to_2023-11-02">VOR</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-11-02_to_2023-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;2, 2023, Vor Biopharma Inc. (the &#8220;Company&#8221;) issued a press release announcing that preclinical and clinical data will be presented at the 65th American Society of Hematology (&#8220;ASH&#8221;) Annual Meeting&#160;&amp; Exposition, being held from December <span style="white-space:nowrap">9-12,</span> 2023, in San Diego, CA. In connection with the announcement, the Company will host a call and webcast on November&#160;2, 2023 at 9:30 a.m. ET. Call details are contained in the press release referenced above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">VBP101 Clinical Update </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> study of <span style="white-space:nowrap">trem-cel</span> (VOR33) in patients with AML, was accepted by ASH for oral presentation. This data supports robust neutrophil engraftment of <span style="white-space:nowrap">trem-cel</span> and provides evidence of hematologic protection from Mylotarg<sup style="font-size:75%; vertical-align:top">TM</sup>, a CD33-targeted antibody drug conjugate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An updated data release from VBP101 is expected by the Relapse After Transplant and Cellular Therapy (HSCT&#178;) conference taking place November <span style="white-space:nowrap">10-11,</span> 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">CD33CART Study Clinical Data Update </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) released data providing a clinical update on a Phase 1/2 study of CD33CART (NCT03971799) , an autologous <span style="white-space:nowrap">CAR-T</span> therapy targeting CD33 (also referred to as VCAR33<sup style="font-size:75%; vertical-align:top">AUTO</sup>) which uses the same <span style="white-space:nowrap">CAR-T</span> construct as VCAR33<sup style="font-size:75%; vertical-align:top">ALLO</sup>. Nineteen pediatric and young adult patients with relapsed/refractory AML with a median age of 16 years were infused in the Phase 1 portion of the study. This data shows that as of the cutoff date of June&#160;1, 2023, 2 of 5 (40%) evaluable patients treated at the highest dose level (DL4, 1 x 10<sup style="font-size:75%; vertical-align:top">7</sup> CAR+ cells/kg) achieved complete remission. Transient CD33CART expansion was detected in 11 (58%) subjects across all doses tested and in all 6 (100%) subjects evaluated at DL4, as of the cutoff date. Four out of 19 evauable patients treated had cytokine release syndrome (CRS) &#8805; Grade 3. The study is being led by Nirali Shah, MD, MHSc, Head, Hematologic Malignancies Section, Pediatric Oncology Branch, National Cancer Institute and Richard Aplenc, MD, PhD, MSCE, Professor of Pediatrics, Children&#8217;s Hospital of Philadelphia (CHOP). This abstract was accepted by ASH for oral presentation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio&#8217;s VCAR33<sup style="font-size:75%; vertical-align:top">ALLO</sup> uses the same <span style="white-space:nowrap">CAR-T</span> construct used in CD33CART. However, VCAR33<sup style="font-size:75%; vertical-align:top">ALLO</sup> uses a potentially superior T cell source from healthy transplant donors, which the Company believes are likely to have a more stem-like phenotype and greater potential for expansion, persistence, and anti-leukemic activity compared to a product derived from autologous sources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Additional ASH Presentations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also released data from a single cell analysis studying molecular signatures from 28 AML patients in various stages of AML progression. This data is the most comprehensive analysis to date on AML profiling. This abstract was accepted by ASH for oral presentation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preclinical collaboration between Vor Bio and Janssen yielded in vitro and in vivo xenotransplant data demonstrating that CD33-deleted allografts were synergistic with Janssen&#8217;s CD33 directed immunotherapy candidate <span style="white-space:nowrap">(JNJ-67571244),</span> and maintained robust <span style="white-space:nowrap">on-target</span> cytotoxicity while reducing production of inflammatory cytokines associated with CRS. This abstract was accepted by ASH for poster presentation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, a <span style="white-space:nowrap"><span style="white-space:nowrap">trial-in-progress</span></span> poster will be presented on the Company&#8217;s VBP301 clinical trial, a Phase 1/2 multicenter, open-label, <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> study of VCAR33<sup style="font-size:75%; vertical-align:top">ALLO</sup> in patients with relapsed or refractory AML after allogeneic stem cell transplantation. This abstract was accepted by ASH for poster presentation. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />&#8195;No.&#8195;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d554165dex991.htm">Press Release, dated November&#160;2, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Vor Biopharma Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Ang</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Robert Ang</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: November&#160;2, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d554165dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g554165g1102013340338.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Multiple Clinical and Preclinical Presentations at ASH 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Highlight Vor Bio&#146;s Novel eHSC and <FONT STYLE="white-space:nowrap">CAR-T</FONT> Platform </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Three oral and two poster presentations accepted by ASH</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Company to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of
Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology at Children&#146;s Hospital of Philadelphia, to discuss abstracts today, November</I><I></I><I>&nbsp;2, at 9.30 AM ET.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., November&nbsp;2, 2023 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company,
today announced that preclinical and clinical data supporting the Company&#146;s novel platform and approach for treating acute myeloid leukemia (AML), will be presented at the 65th American Society of Hematology (ASH) Annual Meeting&nbsp;&amp;
Exposition, being held from December <FONT STYLE="white-space:nowrap">9-12,</FONT> 2023, in San Diego, CA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These three oral and two poster
presentations represent further preclinical and clinical validation of our platform and reflect the significant progress we continue to make as we develop truly novel next generation transplants that have the potential to improve the lives of
patients with blood cancers,&#148; said Dr.&nbsp;Robert Ang, Vor Bio&#146;s President and Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VBP101 Clinical Data Update
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study of <FONT STYLE="white-space:nowrap">trem-cel</FONT> (VOR33) in patients with AML, was accepted by ASH for oral presentation. This data supports robust
neutrophil engraftment of <FONT STYLE="white-space:nowrap">trem-cel</FONT> and provides evidence of hematologic protection from Mylotarg<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, a CD33-targeted antibody drug conjugate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An updated data release from VBP101 is expected by the Relapse After Transplant and Cellular Therapy (HSCT&sup2;) conference taking place November <FONT
STYLE="white-space:nowrap">10-11,</FONT> 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CD33CART Study Clinical Data Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) released data providing a clinical update on a Phase 1/2 study of CD33CART (NCT03971799)<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP>, an autologous <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy targeting CD33 (also referred to as VCAR33<SUP STYLE="font-size:75%; vertical-align:top">AUTO</SUP>) which uses the same <FONT
STYLE="white-space:nowrap">CAR-T</FONT> construct as VCAR33<SUP STYLE="font-size:75%; vertical-align:top">ALLO</SUP>. Nineteen pediatric and young adult patients with relapsed/refractory AML with a median age of 16 years were infused in the Phase 1
portion of the study. This data shows that as of the cutoff date of June&nbsp;1, 2023, 2 of 5 (40%) evaluable patients treated at the highest dose level (DL4, 1 x 10<SUP STYLE="font-size:75%; vertical-align:top">7</SUP> CAR<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> cells/kg) achieved complete remission. Transient CD33CART expansion was detected in 11 (58%) subjects across all doses tested and in all 6 (100%) subjects evaluated at DL4, as of the cutoff date.
Four out of 19 evauable patients treated had cytokine release syndrome (CRS) &#8805; Grade 3. The study is being led by Nirali Shah, MD, MHSc, Head, Hematologic Malignancies Section, Pediatric Oncology Branch, National Cancer Institute and Richard
Aplenc, MD, PhD, MSCE, Professor of Pediatrics, Children&#146;s Hospital of Philadelphia (CHOP). This abstract was accepted by ASH for oral presentation. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsored by the National Marrow Donor Program (NMDP) and Center for International Blood and Marrow Transplant
Research (CIBMTR). Funding by St. Baldrick&#146;s Foundation. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g554165g1102013340338.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah K. Tasian, MD, is a <FONT STYLE="white-space:nowrap">co-investigator</FONT> on the PTCTC-supported
clinical trial and led the preclinical testing and translation of CD33CART with Terry Fry, MD, at the University of Colorado. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Tasian commented:
&#147;The interim results from our CD33 CAR T cell immunotherapy clinical trial are very encouraging. CD33CART is clearly an active therapy based upon our data to date, and the expansion phase of the study will provide additional critical safety and
efficacy data. Our results provide a compelling foundation for Vor Bio&#146;s approach using the same construct for their VBP301 study.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor
Bio&#146;s VCAR33<SUP STYLE="font-size:75%; vertical-align:top">ALLO</SUP> uses the same <FONT STYLE="white-space:nowrap">CAR-T</FONT> construct used in CD33CART. However, VCAR33<SUP STYLE="font-size:75%; vertical-align:top">ALLO </SUP>uses a
potentially superior T cell source from healthy transplant donors, which the Company believes are likely to have a more stem-like phenotype and greater potential for expansion, persistence, and anti-leukemic activity compared to a product derived
from autologous sources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional ASH Presentations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also released data from a single cell analysis studying molecular signatures from 28 AML patients in various stages of AML progression. This data
is the most comprehensive analysis to date on AML profiling. This abstract was accepted by ASH for oral presentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preclinical collaboration
between Vor Bio and Janssen yielded <I>in vitro</I> and <I>in vivo</I> xenotransplant data demonstrating that CD33-deleted allografts were synergistic with Janssen&#146;s CD33 directed immunotherapy candidate
<FONT STYLE="white-space:nowrap">(JNJ-67571244),</FONT> and maintained robust <FONT STYLE="white-space:nowrap">on-target</FONT> cytotoxicity while reducing production of inflammatory cytokines associated with CRS. This abstract was accepted by ASH
for poster presentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">trial-in-progress</FONT></FONT> poster will be
presented on the Company&#146;s VBP301 clinical trial, a Phase 1/2 multicenter, open-label, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study of
VCAR33<SUP STYLE="font-size:75%; vertical-align:top">ALLO</SUP> in patients with relapsed or refractory AML after allogeneic stem cell transplantation. This abstract was accepted by ASH for poster presentation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Full details of the ASH 2023 presentations are as follows: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Vor Bio Clinical Abstracts </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstract Title:
</B><I><FONT STYLE="white-space:nowrap">Trem-cel,</FONT> a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids
Hematopoietic Toxicity During Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)</I> <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Format: </B>Oral
presentation <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>: Gene Therapies: New Approaches from Bench to Bedside<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session date and time: </B>Sunday, December&nbsp;10, 2023, 10:00 AM PST </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstract Title: </B><I>Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or
Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation</I> <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Format: </B>Trial in Progress<B> </B>Poster, #483
<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>: Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session date and time: </B>Monday, December&nbsp;11, 2023, 6:00 PM - 8:00 PM&nbsp;PST </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g554165g1102013340338.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PTCTC Clinical Abstract </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstract Title: </B><I>CD33 CAR <FONT STYLE="white-space:nowrap">T-cells</FONT> (CD33CART) for Children and Young Adults with Relapsed/Refractory AML:
Dose-Escalation Results from a Phase I Multicenter Trial</I> <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Format: </B>Oral presentation <B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>: Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses
in Leukemias and Lymphomas<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session date and time: </B>Monday, December&nbsp;11, 2023, 11:00 AM PST </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Vor Bio Preclinical Abstracts </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstract Title:
</B><I>Multimodal Atlas of Paired Diagnosis and Relapse AML Samples Enables Novel Therapeutic Targeting of Surface Antigens</I> <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Format:
</B>Oral presentation <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and
Prognosis: Biomarkers and Therapeutics<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session date and time: </B>Saturday, December&nbsp;9, 2023, 2:15 PM&nbsp;PST </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstract Summary:</B> The most comprehensive single cell AML atlas known to date (More than 450,000 cells from 28 AML patients) was generated to identify
potential differences in molecular signatures in AML tumor types at multiple stages of AML progression. This extensive AML profiling offers deep insight into cell surface changes during disease progression and reveals the potential for
multi-targeted treatment strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstract Title: </B><I>CD33-Deleted Hematopoietic Cells <FONT STYLE="white-space:nowrap">(trem-cel)</FONT> are
Protected from CD33xCD3 Bispecific Antibody Treatment and Produce Significantly Reduced Levels of Inflammatory Cytokines in Preclinical Studies</I> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Format: </B>Poster, #3425 <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>:
Experimental Transplantation: Basic and Translational: Poster II <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session date and time: </B>Sunday, December&nbsp;10, 2023, 6:00 PM - 8:00
PM&nbsp;PST </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstract Summary:</B> Preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data
resulting from the Company&#146;s strategic collaboration with Janssen, demonstrated that the <I>CD33</I> deleted hematopoietic compartment was protected from Janssen&#146;s CD33 directed immunotherapy
<FONT STYLE="white-space:nowrap">(JNJ-67571244)</FONT> both&nbsp;in cytotoxicity assays and xenotransplantation studies, with reduction of inflammatory cytokines associated with CRS. These findings may enable the development of a next-generation AML
treatment strategy by pairing a <FONT STYLE="white-space:nowrap">trem-cel</FONT> transplant with a subsequent CD33-directed bispecific compound that could enhance the safety and effectiveness of the treatment while decreasing the harmful effect on
the bone marrow. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call&nbsp;&amp; Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Vor Bio management team, joined by Sarah K. Tasian, MD, will conduct a live conference call and webcast to discuss the abstracts, today at 9:30
AM ET. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Listeners can register for the webcast via this <U>LINK.</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Analysts wishing to participate in the Q&amp;A session should use this <U>LINK.</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g554165g1102013340338.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vor Bio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering
hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: <U>www.vorbio.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words
&#147;aim,&#148; &#147;anticipate,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;enable,&#148; &#147;expect,&#148; &#147;initiate,&#148; &#147;intend,&#148; &#147;may,&#148;
<FONT STYLE="white-space:nowrap">&#147;on-track,&#148;</FONT> &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;should,&#148; &#147;target,&#148; &#147;update,&#148; &#147;will,&#148; &#147;would,&#148; and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio&#146;s statements regarding the potential of its product
candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, the timing and pace of patient enrollment in clinical trials and the availability of data therefrom, the expected safety profile of
its product candidates, the potential of <FONT STYLE="white-space:nowrap">trem-cel</FONT> to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted <FONT STYLE="white-space:nowrap">CAR-Ts,</FONT> and the
potential superiority of the <FONT STYLE="white-space:nowrap">T-cell</FONT> source of VCAR33<SUP STYLE="font-size:75%; vertical-align:top">ALLO</SUP> compared to VCAR33<SUP STYLE="font-size:75%; vertical-align:top">AUTO</SUP>. Vor Bio may not
actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor
Bio&#146;s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials;
whether results from preclinical studies and clinical trials of VCAR33<SUP STYLE="font-size:75%; vertical-align:top">AUTO</SUP> will be replicated or superior in those of VCAR33<SUP STYLE="font-size:75%; vertical-align:top">ALLO</SUP>, whether
successful engraftment and platelet recovery will ultimately lead to efficacy of <FONT STYLE="white-space:nowrap">trem-cel;</FONT> expectations for regulatory approvals to conduct trials or to market products; the success of Vor Bio&#146;s <FONT
STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are
described in greater detail under the caption &#147;Risk Factors&#148; included in Vor Bio&#146;s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking
statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be
required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media&nbsp;&amp;
Investors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah Spencer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-242-6076</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>sspencer@vorbio.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vor-20231102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 11/2/2023 2:56:17 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:vor="http://vorbiopharma.com/20231102"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://vorbiopharma.com/20231102"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vor-20231102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vor-20231102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vor-20231102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 11/2/2023 2:56:17 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>vor-20231102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 11/2/2023 2:56:17 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vor-20231102.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g554165g1102013340338.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g554165g1102013340338.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U )(# 2(  A$! Q$!_\0
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M:X=-F?%O>X5<GA9!T_/I^5>S30QW$$D$R!XI%*.IZ$'@BOGGQ+HL_ACQ%+;
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%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139657392805936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001817229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vor Biopharma Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1591163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cambridgepark Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-6580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d554165d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vor-20231102.xsd" xlink:type="simple"/>
    <context id="duration_2023-11-02_to_2023-11-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817229</identifier>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-11-02_to_2023-11-02">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-11-02_to_2023-11-02"
      id="Hidden_dei_EntityCentralIndexKey">0001817229</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-11-02_to_2023-11-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-11-02_to_2023-11-02">2023-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-11-02_to_2023-11-02">Vor Biopharma Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-11-02_to_2023-11-02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-11-02_to_2023-11-02">001-39979</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-11-02_to_2023-11-02">81-1591163</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-11-02_to_2023-11-02">100 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-11-02_to_2023-11-02">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-11-02_to_2023-11-02">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-11-02_to_2023-11-02">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-11-02_to_2023-11-02">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-11-02_to_2023-11-02">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-11-02_to_2023-11-02">655-6580</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-11-02_to_2023-11-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-11-02_to_2023-11-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-11-02_to_2023-11-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-11-02_to_2023-11-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-11-02_to_2023-11-02">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-11-02_to_2023-11-02">VOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-11-02_to_2023-11-02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-11-02_to_2023-11-02">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-11-02_to_2023-11-02">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVBT_RA9D+FU4N_P:1-P,\WV*"M[.R,_^A=O1$NA,9,.C3) 4IFI@GX0B5QV
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( %U)8E?]!)[>[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( %U)8E>97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 74EB
M5X(Y9!%[!   RQ$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( %U)8E>?H!OPL0(  .(,   -
M      "  ;X,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 74EB5Y>*NQS
M    $P(   L              ( !F@\  %]R96QS+RYR96QS4$L! A0#%
M  @ 74EB5QPX9>H_ 0  / (   \              ( !@Q   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( %U)8E<D'INBK0   /@!   :
M  "  >\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M %U)8E=ED'F2&0$  ,\#   3              "  =02  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  !X4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d554165d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d554165d8k.htm">d554165d8k.htm</File>
    <File>vor-20231102.xsd</File>
    <File>vor-20231102_lab.xml</File>
    <File>vor-20231102_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d554165d8k.htm": {
   "nsprefix": "vor",
   "nsuri": "http://vorbiopharma.com/20231102",
   "dts": {
    "inline": {
     "local": [
      "d554165d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "vor-20231102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "vor-20231102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vor-20231102_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "report": {
    "R1": {
     "role": "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-11-02_to_2023-11-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d554165d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-11-02_to_2023-11-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d554165d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://vorbiopharma.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-268939-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-268939-xbrl.zip
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MU8IP-VG(E:B6G<,'9A^W2#N,5K5UH&T :V5_?&A]G337R]M/FA:UI('J":"
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ME?H>N(*6CUBE_0<SY*+5)N?#T!=C)E^=);,&E5R)PH0S2TS?%&)9M&%)SAZ
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MB ;=-(2;L&(?0 8%4GR^OMF+!3V%?%M F>=VXW$Z*EW)$VW-CHQ>8D$2'2D
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MRTR*-(_C*,EH'3I-*Y+NT$(V?[&S8W2[C.,DDMX8+$E$!J7E>Z670R0G4Q5
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M1&9^ P]E\L<8L8!OR8")=AL7Y1U7:DO_=:%\%\W^QH[:\S]02P,$%     @
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M,38U9&5X.3DQ+FAT;5!+ 0(4 Q0    ( %U)8E=L?1R</@,  $D+   0
M          "  :(N  !V;W(M,C R,S$Q,#(N>'-D4$L! A0#%     @ 74EB
M5WY_"#&J!@  I$D  !0              ( !#C(  '9O<BTR,#(S,3$P,E]L
M86(N>&UL4$L! A0#%     @ 74EB5V(8#=?=!   _BT  !0
M ( !ZC@  '9O<BTR,#(S,3$P,E]P<F4N>&UL4$L%!@     %  4 /0$  /D]
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
